- Home
- CDNA vs STK Comparison
CDNA vs STK Comparison
Compare CDNA & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- STK
- Stock Information
- Founded
- CDNA 1998
- STK 2009
- Country
- CDNA United States
- STK United States
- Employees
- CDNA N/A
- STK N/A
- Industry
- CDNA Medical Specialities
- STK Investment Managers
- Sector
- CDNA Health Care
- STK Finance
- Exchange
- CDNA Nasdaq
- STK Nasdaq
- Market Cap
- CDNA 712.2M
- STK 614.2M
- IPO Year
- CDNA 2014
- STK N/A
- Fundamental
- Price
- CDNA $14.45
- STK $35.61
- Analyst Decision
- CDNA Buy
- STK
- Analyst Count
- CDNA 8
- STK 0
- Target Price
- CDNA $26.86
- STK N/A
- AVG Volume (30 Days)
- CDNA 1.3M
- STK 38.2K
- Earning Date
- CDNA 11-03-2025
- STK 01-01-0001
- Dividend Yield
- CDNA N/A
- STK 6.60%
- EPS Growth
- CDNA N/A
- STK N/A
- EPS
- CDNA 1.00
- STK N/A
- Revenue
- CDNA $340,826,000.00
- STK N/A
- Revenue This Year
- CDNA $12.73
- STK N/A
- Revenue Next Year
- CDNA $11.90
- STK N/A
- P/E Ratio
- CDNA $14.57
- STK N/A
- Revenue Growth
- CDNA 14.72
- STK N/A
- 52 Week Low
- CDNA $10.96
- STK $24.95
- 52 Week High
- CDNA $31.52
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- CDNA 50.12
- STK 58.16
- Support Level
- CDNA $13.95
- STK $34.91
- Resistance Level
- CDNA $15.50
- STK $36.25
- Average True Range (ATR)
- CDNA 0.55
- STK 0.64
- MACD
- CDNA -0.10
- STK -0.15
- Stochastic Oscillator
- CDNA 32.26
- STK 50.16
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.